Cabanillas Beatriz, Murdaca Giuseppe, Guemari Amir, Torres Maria Jose, Azkur Ahmet Kursat, Aksoy Emel, Vitte Joana, Fernández-Santamaria Ruben, Karavelia Aspasia, Castagnoli Riccardo, Valdelvira Rafael, Orsi Andrea, Ogliastro Matilde, Massaro Elvira, Yücel Esra Özek, Novak Natalija, Agache Ioana, Akdis Mubeccel, Akdis Cezmi A
Department of Allergy, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Department of Internal Medicine, University of Genova, Genova, Italy.
Allergy. 2024 Dec;79(12):3285-3309. doi: 10.1111/all.16374. Epub 2024 Nov 4.
As the world still vividly recalls the previous monkeypox (mpox) outbreak that impacted over 120 countries worldwide with more than 99,000 cases in 2022, we are now facing a second wave of infections from the monkeypox virus (MPXV), characterized by an exponential increase in cases. The current 2024 outbreak has already recorded more than 20,000 cases in Africa, marking a dramatic escalation compared to previous outbreaks. The predominance of the newly identified clade Ib variant, first detected in the Democratic Republic of the Congo (DRC) and now identified across multiple African nations and beyond, underscores its enhanced transmissibility and potential for international spread, evidenced by cases in Sweden and Thailand. The World Health Organization (WHO) declared on August 14, 2024, the current mpox outbreak a Public Health Emergency of International Concern (PHEIC), calling for heightened global public health measures. The ongoing pattern of unusual, frequent, and extensive outbreaks of mpox with potential global implications poses significant questions. This review addresses, in the format of 50 questions and answers, the 2024 mpox outbreak, detailing its characteristics, epidemiological data, and impact compared to previous outbreaks. It comprehensively explores critical questions related to MPXV virological characteristics, immunological response, clinical manifestations, epidemiology, diagnostics, and available treatments. The review also documents the significant and evolving challenges posed by the current mpox outbreak, highlighting its scale, spread, and public health response.
全世界仍清晰地记得上一次猴痘疫情,该疫情在2022年影响了全球120多个国家,病例超过99000例。如今,我们正面临猴痘病毒(MPXV)引发的第二轮感染潮,其特点是病例呈指数级增长。2024年的此次疫情在非洲已记录了超过20000例病例,与之前的疫情相比大幅升级。新发现的进化枝Ib变种占主导地位,该变种最初在刚果民主共和国被检测到,如今在多个非洲国家及其他地区都有发现,这凸显了其更强的传播性和国际传播潜力,瑞典和泰国出现的病例就是明证。世界卫生组织(WHO)于2024年8月14日宣布当前的猴痘疫情为国际关注的突发公共卫生事件(PHEIC),呼吁加强全球公共卫生措施。猴痘持续出现异常、频繁且广泛的疫情爆发模式,并可能产生全球影响,这引发了重大问题。本综述以50个问答的形式阐述了2024年猴痘疫情,详细介绍了其特征、流行病学数据以及与之前疫情相比的影响。它全面探讨了与MPXV病毒学特征、免疫反应、临床表现、流行病学、诊断和现有治疗方法相关的关键问题。该综述还记录了当前猴痘疫情带来的重大且不断演变的挑战,突出了其规模、传播范围和公共卫生应对措施。